Details for Patent: 11,085,043

Which drugs does patent 11,085,043 protect, and when does it expire?

Patent 11,085,043 protects DEFITELIO and is included in one NDA.

This patent has twenty-five patent family members in sixteen countries.

Summary for Patent: 11,085,043

Patent landscape, scope, and claims:

Title:	Euglobulin-based method for determining the biological activity of defibrotide
Abstract:	It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.
Inventor(s):	Terenzio Ignoni, Vijay Kumar, Khalid Islam
Assignee:	Gentium SRL
Application Number:	US16/816,741
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 11,085,043

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Jazz Pharms Inc	DEFITELIO	defibrotide sodium	SOLUTION;INTRAVENOUS	208114-001	Mar 30, 2016		RX	Yes	Yes	11,085,043		Y

International Family Members for US Patent 11,085,043

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012383169
Brazil	112014031934
Canada	2874960
China	104619857